LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is scheduled to participate in the following upcoming investor conferences: 9th Annual ...
AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife generated double-digit year-over-year growth, while AlphaVac bounced back strongly on a sequential basis, and gross margin improved more than three points. Execution remains the key here, as Auryon, Al...
AngioDynamics Inc. (NASDAQ:ANGO ) Q4 2024 Earnings Conference Call July 16, 2024 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participants John Young - Canaccord Genuity Steve Lichtman - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics fiscal year 2024 Fourth Quarter Earnings Call.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2024 before the market open on Tuesd...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) were presented...
AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a large ($2B+) and growing market. The company's historical execution challenges raise concerns, b...
AngioDynamics Inc. (NASDAQ:ANGO ) Q3 2024 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice President, Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer & Co. John Young - Canaccord Genuity Operator Good morning and welcome to the...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.